US5423320A Andrew L. Salzman Argus Critical Care, Inc.
Priority 1993-04-20 • Filed 1993-04-20 • Granted 1995-06-13 • Published 1995-06-13
A method and apparatus for measuring or monitoring pCO2 , and optionally pO2 , on a real-time basis, in the stomach or the intestine using air tonometry. The intraluminal measurements are made using a catheter having a CO2 sensor, and optionally a pO2 sensor, at its tip for in situ measurements, or …
Mercapto derivatives as inhibitors of nitric oxide synthase
US5674907A Andrew L. Salzman Children's Hospital Medical Center
Priority 1995-03-24 • Filed 1995-03-24 • Granted 1997-10-07 • Published 1997-10-07
This invention is directed to a pharmacologically acceptable composition for inhibiting nitric oxide synthase in a mammal, which includes a mercapto derivative and a pharmaceutically acceptable carrier. The invention also concerns a method of inhibiting nitric oxide synthase, selectively …
Mercapto and seleno derivatives as inhibitors of nitric oxide synthase
EP AU CA CZ DK HU NZ TR US5929063A Andrew L. Salzman Children's Hospital Medical Center
Priority 1995-03-24 • Filed 1995-10-20 • Granted 1999-07-27 • Published 1999-07-27
This invention is directed to a pharmacologically acceptable composition for inhibiting nitric oxide synthase in a mammal, which includes a mercapto or seleno derivative and a pharmaceutically acceptable carrier. The invention also concerns a method of inhibiting nitric oxide synthase, selectively …
Pharmaceutical method for the treatment of severe blood loss and for the …
JP BR CZ IL NO US5856360A Andrew L. Salzman Children's Hospital Medical Center
Priority 1996-05-03 • Filed 1996-05-03 • Granted 1999-01-05 • Published 1999-01-05
This invention is directed to a pharmacologically acceptable composition for inhibiting or treating hemorrhagic shock in a mammal. The composition includes a K ATP inhibitor and a pharmacologically acceptable carrier, with the K ATP inhibitor being present in an amount sufficient to inhibit or treat …
Nitric oxide donor compounds and pharmaceutical compositions for pulmonary …
JP AR ZA US5958427A Andrew L. Salzman Salzman; Andrew L.
Priority 1996-11-08 • Filed 1996-11-08 • Granted 1999-09-28 • Published 1999-09-28
The invention is directed to nitric oxide (NO) donor compounds and to pharmaceutical compositions containing such nitric oxide (NO) donor compounds, for delivering NO to the apical surface of a mucosa, where the nitric oxide is released for passage across the epithelial monolayer of the mucous …
Mercapto derivatives as inhibitors of cyclooxygenases
CA2247121A1 Andrew Salzman Andrew Salzman
Priority 1996-03-05 • Filed 1997-03-03 • Published 1997-09-12
This invention is directed to a pharmacologically acceptable composition for inhibiting cyclooxygenase in a mammal, which includes a mercapto derivative and a pharmaceutically acceptable carrier. The invention also concerns a method of inhibiting cyclooxygenase and treating various conditions …
Mercapto derivatives as inhibitors of cyclooxygenases
WO JP TR WO1997032575A1 Andrew Salzman Children's Hospital Medical Center
Priority 1996-03-05 • Filed 1997-03-03 • Published 1997-09-12
This invention is directed to a pharmacologically acceptable composition for inhibiting cyclooxygenase in a mammal, which includes a mercapto derivative and a pharmaceutically acceptable carrier. The invention also concerns a method of inhibiting cyclooxygenase and treating various conditions …
Guanidino derivatives as inhibitors of the cytotoxic effect of peroxynitrite
WO WO1997045108A1 Andrew L. Salzman Children's Hospital Medical Center
Priority 1996-05-30 • Filed 1997-05-16 • Published 1997-12-04
This invention is directed to a pharmacologically acceptable composition for inhibiting the cytotoxic effect of peroxynitrite in a mammal, which includes a guanidino derivative and a pharmaceutically acceptable carrier. The invention also concerns a method of inhibiting the cytotoxic effect of …
Mercapto and seleno derivatives as inhibitors of nitric oxide synthase
AU AU729933B2 Andrew L Salzman Children's Hospital Medical Center
Priority 1995-03-24 • Filed 1998-11-16 • Granted 2001-02-15 • Published 2001-02-15
A compound having a formula selected from the group consisting of: N-R 3 II R 1 Y-Z-X-C NH-R2 and NH R N-R 3 I I I C-X' z'-S -S -Z-X-C R'3 NH-R 2 or a salt thereof, wherein R is H, alkyl, alkenyl, phenyl. alkylene, alkenylene, or phenylalkylene or a substituted derivative thereof; when R, is …
Substituted phenanthridinones and methods of use thereof
US6277990B1 Andrew Salzman Inotek Corporation
Priority 1999-12-07 • Filed 1999-12-07 • Granted 2001-08-21 • Published 2001-08-21
This invention provides a novel class of substituted 6(5H)phenanthridinone compounds. Pharmaceutical compositions, and methods of making and using the compounds, or a pharmaceutically acceptable salt, hydrate, prodrug, or mixture thereof are also described.
Substituted phenanthridinones and methods of use thereof
US6476048B1 Andrew Salzman Inotek Pharamaceuticals Corporation
Priority 1999-12-07 • Filed 2000-06-22 • Granted 2002-11-05 • Published 2002-11-05
This invention provides a novel class of substituted 6(5H)phenanthridinone compounds. Pharmaceutical compositions, and methods of making and using the compounds, or a pharmaceutically acceptable salt, hydrate, prodrug, or mixture thereof are also described.
Methods for the treatment of neurodegenerative disorders using substituted …
US6531464B1 Andrew Salzman Inotek Pharmaceutical Corporation
Priority 1999-12-07 • Filed 2000-06-29 • Granted 2003-03-11 • Published 2003-03-11
This invention provides a novel class of substituted 6(5H)phenanthridinone compounds. The invention also includes pharmaceutical compositions, and methods of making and using the compounds, or a pharmaceutically acceptable salt, hydrate, prodrug, or mixture thereof. Methods of using the compounds …
Compositions and method for treatment of acetaminophen intoxication
WO US6281222B1 Andrew L. Salzman Inotek Corporation
Priority 1999-08-19 • Filed 2000-08-17 • Granted 2001-08-28 • Published 2001-08-28
The invention provides compositions and methods for treatment of acetaminophen intoxication using an inhibitor of xanthine oxidase that does not induce superoxide radical formation when introduced into a subject. An example of a xanthine oxidase inhibitor that can be used according to the …
Composition and method for treating a microbial infection
WO AU4709401A Andrew L Salzman Inotek Corporation
Priority 1999-11-29 • Filed 2000-11-29 • Published 2001-06-12
Inhibitors of inflammation and reperfusion injury and methods of use thereof
WO US AU US20020095044A1 Andrew Salzman Prakash Jagtap
Priority 2000-04-06 • Filed 2001-01-19 • Published 2002-07-18
The invention provides a novel class of substituted isoindolinone derivatives. Pharmaceutical compositions, and methods of making and using the compounds, or pharmaceutically acceptable salts, hydrates, prodrugs, or mixtures thereof are also described.
Method and composition for modulating an immune response
WO JP US20010053763A1 Andrew Salzman Andrew Salzman
Priority 1998-12-02 • Filed 2001-03-26 • Published 2001-12-20
Disclosed is a method of inhibiting or preventing a condition associated with undesired secretion of a macrophage inflammatory protein using inhibitors of ATP-sensitive K + -channels, inhibitors of the Na + /H + antiporter, inosine, or inosine analogs.
Inhibitors of inflammation and reperfusion injury and methods of use thereof
AU2001249918A1 Andrew Salzman Inotek Corporation
Priority 2000-04-06 • Filed 2001-04-06 • Published 2001-10-23
Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof
WO EP US JP AU DE EC ES IL MX NO ZA US20030096833A1 Andrew Salzman Jagtap Prakash G.
Priority 2001-08-31 • Filed 2001-08-31 • Published 2003-05-22
The invention provides a novel class of substituted indeno[1,2-c]isoquinoline derivatives. Pharmaceutical compositions and methods of making and using the compounds, are also described.
Inosine compounds and their use for treating or preventing an inflamation or a …
AU2002255927A1 Andrew Salzman Inotek Pharmaceuticals Corporation
Priority 2001-03-26 • Filed 2002-03-26 • Published 2002-10-08
Inosine compounds and their use for treating or preventing an inflammation or a …
US US6958324B2 Andrew L. Salzman Inotek Pharmaceuticals Corporation
Priority 1998-12-02 • Filed 2002-03-26 • Granted 2005-10-25 • Published 2005-10-25
Inosine compounds, compositions comprising an inosine compound and methods for treating or preventing an inflammation disease or a reperfusion disease comprising administering an effective amount of an inosine compound to a patient in need thereof are disclosed.
5-Aryltetrazole Compounds, compositions thereof, and uses therefor
US JP HU IL MX NZ PL ZA US20040019208A1 Andrew Salzman Alex Nivorozhkin
Priority 2002-07-18 • Filed 2002-07-18 • Published 2004-01-29
The present invention relates to 5-Aryltetrazole compounds, compositions comprising a 5-Aryltetrazole compound, and methods for treating an inflammation disease, a reperfusion disease, hyperuricemia, gout, or tumor-lysis syndrome in an animal in need thereof comprising administering to the animal …
Substituted indeno[1,2-c]isoquinoline derivatives and methods of use thereof
WO EP US JP AU DE EC ES IL MX NO ZA AU2002329920A1 Andrew L. Salzman Inotek Pharmaceuticals Corporation
Priority 2001-08-31 • Filed 2002-08-30 • Published 2003-06-05
Isoquinoline derivatives and methods of use thereof
WO US JP PL US6956035B2 Andrew L. Salzman Inotek Pharmaceuticals Corporation
Priority 2001-08-31 • Filed 2003-02-28 • Granted 2005-10-18 • Published 2005-10-18
The invention provides novel classes of Isoquinoline Derivatives. Pharmaceutical compositions and methods of making and using the compounds, are also described.
5-Aryltetrazole compounds, compositions thereof, and uses therefor
US AR US20040116423A1 Andrew Salzman Alex Nivorozhkin
Priority 2002-07-18 • Filed 2003-07-17 • Published 2004-06-17
The present invention relates to 5-Aryltetrazole Compounds, compositions comprising an effective amount of a a 5-Aryltetrazole Compound, and methods for treating an inflammation disease, a reperfusion disease, or hyperuricemia in an animal in need thereof comprising administering to the animal an …
5-aryltetrazole compounds, compositions thereof, and uses therefor
TW TW200510348A Andrew L Salzman Inotek Pharmaceuticals Corp
Priority 2003-07-17 • Filed 2004-07-16 • Published 2005-03-16
The present invention relates to 5-Aryltetrazole Compounds, compositions comprising an effective amount of a 5-Aryltetrazole Compound, and methods for treating an inflammation disease, a reperfusion disease, or hyperuricemia in an animal in need thereof comprising administering to the animal an …
Izochynolyn derivatives and the method of their application
PL PL381202A1 Andrew L. Salzman Inotek Pharmaceuticals Corporation
Priority 2005-02-25 • Filed 2005-02-25 • Published 2007-05-14
Isoquinoline derivatives and methods of use thereof
WO EA IL ZA EP1722797A1 Andrew L. Salzman Inotek Pharmaceuticals Corporation
Priority 2004-02-26 • Filed 2005-02-25 • Published 2006-11-22
The present invention relates to Isoquinoline Derivatives, compositions comprising an effective amount of a Isoquinoline Derivative and methods for treating or preventing an inflammatory disease, a reperfusion injury, an ischemic condition, renal failure, diabetes, a diabetic complication, a …
Pure derivatives than adenosine a1 receptor agonists and method for the …
WO EP US JP AT AU CA CY DE DK ES HR ME MX PL PT RS AT462704T Andrew Salzman Inotek Pharmaceuticals Corp
Priority 2004-05-26 • Filed 2005-05-25 • Published 2010-04-15
Purine derivatives as adenosine a1 receptor agonists and methods of use thereof
SI SI1758596T1 Andrew L Salzman Inotek Pharmaceutical Corp
Priority 2004-05-26 • Filed 2005-05-25 • Published 2010-12-31
Methods for treating or preventing erectile dysfunction or urinary incontinence
WO JP IL EP1784186A2 Andrew L. Salzman Inotek Pharmaceuticals Corporation
Priority 2004-06-16 • Filed 2005-06-15 • Published 2007-05-16
The present invention relates to methods for treating or preventing erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of a compound of the invention.
Purine derivatives and methods of use thereof
WO EP US JP AT AU IL MX ZA EP1802316B1 Andrew L. Salzman Inotek Pharmaceuticals Corporation
Priority 2004-09-20 • Filed 2005-09-19 • Granted 2011-11-02 • Published 2011-11-02
The invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for treating or preventing an ischemic condition, reperfusion injury, a cellular proliferative disorder, a cardiovascular disease, a neurological disorder, a skin disorder, …
Purine derivatives and methods of use thereof
WO US JP AU ZA EP1962597A2 Andrew L. Salzman Inotek Pharmaceuticals Corporation
Priority 2005-11-30 • Filed 2006-11-30 • Published 2008-09-03
The present invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal's core body temperature, protecting an animal's heart against myocardial damage during cardioplegia; or for treating or preventing a …
Methods for treating or preventing erectile dysfunction or urinary incontinence
WO WO2007117289A3 Andrew L Salzman Inotek Pharmaceuticals Corp
Priority 2005-12-14 • Filed 2006-12-11 • Published 2008-01-03
The invention relates to methods for treating or preventing erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of a compound of the invention.
Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof
CN ZA ZA200610532B Andrew L Salzman Inotek Pharmaceuticals Corp
Priority 2004-05-26 • Filed 2006-12-14 • Published 2009-09-30
Purine compounds and methods of use thereof
WO JP IL AU2007229463A1 Andrew L. Salzman Inotek New Zealand Limited
Priority 2006-03-23 • Filed 2007-03-22 • Published 2007-10-04
A compound of Formula (I): A O D B C or a pharmaceutically acceptable salt thereof, wherein A is -C(O)NHR 3 , -CH 2 NHR", -CH 2 OSO 2 NH 2 , -CH 2 ONO 2 , -CH 2 ONO, CH 2 OSO 3 H, -CH 2 OSO 2 NH(CI-Co 0 alkyl), -CH 2 OSO 2 N(CI -C 10 alkyl) 2 , -CH 2 OH or 0 CH2OSO 2 NH-aryl, where each CI-Clo …
Antibodies against flagellin and uses thereof
WO US WO2009033013A4 Andrew L Salzman Nurit Rachamim
Priority 2007-09-05 • Filed 2008-09-05 • Published 2009-04-16
The present invention provides a novel class of monoclonal antibodies which have a high affinity, broad spectrum neutralizing reactivity to flagellin from various Gram-negative bacteria including, but not limited to, E. coli, Salmonella, Serratia, Proteus, Enterobacter, Citrobacter, Campylobacter …
Purine compounds and methods of use thereof
ZA ZA200807956B Andrew L Salzman Inotek Phamaceuticals Corp
Priority 2006-03-23 • Filed 2008-09-16 • Published 2009-07-29
Antibodies against flagellin and uses thereof
US20100239583A1 Andrew L. Salzman Inotek Pharmaceuticals Corporation
Priority 2009-03-04 • Filed 2010-03-04 • Published 2010-09-23
The present invention provides a novel class of monoclonal antibodies which have a high affinity, broad spectrum neutralizing reactivity to flagellin from various Gram-negative bacteria including, but not limited to, E. coli, Salmonella, Serratia, Proteus, Enterobacter, Citrobacter, Campylobacter …
Compositions and methods for prevention and treatment of pulmonary hypertension
WO AU2011210352A1 Andrew Lurie Salzman Radikal Therapeutics Inc.
Priority 2010-01-26 • Filed 2011-01-26 • Published 2012-08-09
The invention provides compositions and methods for prevention, treatment, or management of pulmonary hypertension using piperidine, pyrrolidine, or azepane derivatives comprising one to four nitric oxide (NO) donor groups and a reactive oxygen species (ROS) degradation catalyst. The invention …
Lipoic acid and nitroxide derivatives and uses thereof
WO US20130116284A1 Andrew Lurie Salzman Radikal Therapeutics Inc.
Priority 2010-05-10 • Filed 2011-05-09 • Published 2013-05-09
Provided are bifunctional compounds comprising a poly(ADP-ribose) polymerase (PARP) inhibitor moiety and a reactive oxygen species (ROS) scavenger moiety, more particularly, a lipoic acid or cyclic nitroxide derivative, covalently attached either directly or via a linker, as well as pharmaceutical …
Compositions and methods for treatment of sepsis and related conditions
WO WO2012093383A1 Andrew Lurie Salzman Radikal Therapeutics Inc.
Priority 2011-01-04 • Filed 2011-11-15 • Published 2012-07-12
The invention provides compositions and methods for treatment of sepsis and conditions associated therewith using piperidine, pyrrolidine, or azepane derivatives comprising one to four nitric oxide (NO) donor groups and a reactive oxygen species (ROS) degradation catalyst.
Multifunctional nitroxide derivatives and uses thereof
WO EP US JP AU BR DK ES HR HU PL PT RS RU SI AU2011340037B2 Andrew Lurie Salzman Tisbury Pharmaceuticals, Inc.
Priority 2010-12-09 • Filed 2011-12-08 • Granted 2016-03-17 • Published 2016-03-17
The present invention provides multifunctional nitroxide derivatives comprising a potassium channel opener and a reactive oxygen species (ROS) degradation catalyst that can act as an anti-oxidant, as well as pharmaceutical compositions comprising them. The multifunctional compounds and …
Compositions and methods for treatment of renal ischemia-reperfusion injury
WO WO2013005216A1 Andrew Lurie Salzman Radikal Therapeutics Inc.
Priority 2011-07-05 • Filed 2012-07-04 • Published 2013-01-10
The invention provides compositions and methods for prevention or treatment of renal ischemia-reperfusion injury using piperidine, pyrrolidine, or azepane derivatives comprising one to four nitric oxide donor groups and a reactive oxygen species (ROS) degradation catalyst.
Prodrugs of multifunctional nitroxide derivatives and uses thereof
WO EP US CN JP AU BR DK ES HR HU PL PT SI US20160002171A1 Andrew Lurie Salzman Radikal Therapeutics Inc.
Priority 2013-03-05 • Filed 2013-03-05 • Published 2016-01-07
Prodrugs of compounds comprise a nitric oxide donor and a reactive oxygen species (ROS) degradation catalyst, in particular, 1-pyrrolidinyloxy, 1-piperidinyloxy, and 1-azepanyloxy derivatives, and pharmaceutical compositions thereof. These compounds and pharmaceutical compositions are useful in …
Compositions and methods for treatment of inflammatory diseases of the lung
WO US20150368197A1 Andrew Lurie Salzman Radikal Therapeutics Ins.
Priority 2012-06-21 • Filed 2013-06-20 • Published 2015-12-24
Pharmaceutical compositions and methods are for treatment of an inflammatory disease of the lung caused by inhalation of a toxic agent or an irritant. In one example, chlorine inhalational lung injury can be treated using compounds useful in such compositions.
Thioredoxin mimetic prodrugs and uses thereof
WO WO2016009341A1 Andrew Lurie Salzman Radikal Therapeutics Inc.
Priority 2014-07-14 • Filed 2015-07-14 • Published 2016-01-21
The present invention provides thioredoxin (TRX) mimetic prodrugs, more particularly, derivatives or analogues of the amino acid sequence Cys-Pro-Cys or A 1 -Cys- A 2 -Pro-A 3 -Cys-A 4 wherein A 1 to A 4 each independently is either absent or an amino acid residue, as well as pharmaceutical compositions …
Methods and pharmaceutical compositions for treatment of lung inflammation
WO WO2017077528A3 Andrew Lurie Salzman Salzman Lovelace Investments, Ltd.
Priority 2015-11-02 • Filed 2016-10-31 • Published 2017-08-03
The present invention relates to use of resolvin molecules selected from mono- or poly-hydroxylated eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), or n-3 docosapentanoic acid (n-3 DPA), e.g., Rv E1, or pharmaceutically acceptable salts, esters, or amides thereof, for preventing or …
Pharmaceutical composition and method for reducing intraocular pressure
WO WO2017208129A1 Andrew Lurie Salzman Tisbury Pharmaceuticals, Inc.
Priority 2016-05-31 • Filed 2017-05-29 • Published 2017-12-07
The present invention relates to a pharmaceutical composition comprising the oxy radical of 2-cyano-1-(1-hydroxy-2,2,5,5-tetramethylpyrrolidin-3-yl)-3-(pyridin-3-yl) guanidine, or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt, solvate or prodrug thereof, for reducing …
CBD prodrugs, compositions, and methods of administering cbd and cbd prodrugs
WO WO2018096504A1 Andrew Salzman Kalytera Therapeutics, Inc
Priority 2016-11-28 • Filed 2017-11-27 • Published 2018-05-31
Compounds of Formula (I), including stereoisomers and salts thereof, and compositions, methods of treatment and prevention, and methods of preparing, the same: Formula (I) wherein X is O or a direct bond; wherein when X is O, R 1 and R 2 are each independently selected from -H, -SO 3 Na, -PO(ONa) 2 , - …
Methods for synthesis of resolvins
WO WO2019049138A1 Andrew Lurie Salzman Salzman Investments, Ltd.
Priority 2017-09-11 • Filed 2018-09-06 • Published 2019-03-14
The present invention provides methods for chemical synthesis of a resolvin compound such as resolvin E1 (RvE1), or a pharmaceutically acceptable salt thereof; and chemically stable formulations of said compound.
Cannabinoid derivatives and conjugates and uses thereof
WO US CA CA3091088A1 Andrew Lurie Salzman Beetlebung Pharma Ltd.
Priority 2018-02-13 • Filed 2019-02-13 • Published 2019-08-22
The present invention provides cannabinoid derivatives, more specifically cannabidiol (CBD), desoxy-CBD, and desoxy-A9- tetrahydrocannabinol (desoxy-THC) derivatives, which are useful for neuroprotection, treating pain, or treating a disease associated with alpha-1 glycine receptor (alGlyR) and/or …
